Q-omics provides the consensus-scored PDP1 profile across patient tissues and cancer cell-line models. PDP1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, PDP1 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, PDP1 RNA expression shows 20,203 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight OV, COAD, and UVM as cancer lineages where PDP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDP1 survival associations across molecular data types. PDP1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDP1 RNA expression–survival associations across cancer types. High PDP1 expression shows unfavorable associations in OV, MESO, UVM and BRCA, but favorable associations in KIRP and ACC. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for PDP1 RNA expression.
This table summarizes PDP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PDP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDP1 shows lower tumor expression in KIRC and higher tumor expression in COAD, HNSC, KICH, LUAD and STAD. The COAD box plot shows higher PDP1 RNA expression in tumor versus normal tissue (log2 FC = +1.338, t-test p < 0.001).
This table shows molecular features associated with PDP1 in patient tissues and cancer cell lines. In patient samples, PDP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
